CN101148459A - High-purity scutellarin salt and slow release preparation - Google Patents
High-purity scutellarin salt and slow release preparation Download PDFInfo
- Publication number
- CN101148459A CN101148459A CNA2007100661930A CN200710066193A CN101148459A CN 101148459 A CN101148459 A CN 101148459A CN A2007100661930 A CNA2007100661930 A CN A2007100661930A CN 200710066193 A CN200710066193 A CN 200710066193A CN 101148459 A CN101148459 A CN 101148459A
- Authority
- CN
- China
- Prior art keywords
- salt
- purity
- breviscapine
- scutellarin salt
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical class O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title abstract description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000003756 stirring Methods 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004925 Acrylic resin Substances 0.000 claims abstract description 6
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 6
- 238000009835 boiling Methods 0.000 claims abstract description 5
- 239000003513 alkali Substances 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 229920000178 Acrylic resin Polymers 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000012670 alkaline solution Substances 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000012452 mother liquor Substances 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 abstract description 14
- 150000003839 salts Chemical class 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 2
- 238000000151 deposition Methods 0.000 abstract 1
- 239000012065 filter cake Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 3
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229930190376 scutellarin Natural products 0.000 description 3
- -1 scutellarin arginic acid salt Chemical class 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to high purity breviscapine B salt as one new type of medicinal material and the oral preparation prepared with it as the active component. High purity breviscapine B salt is prepared with breviscapine B in purity higher than 99 %, and through dissolving in boiling water in 3-5 times weight, adding alkali solution to regulate pH value of the solution to 6.7-7.5 and produce breviscapine B salt, adding acetone in 5-10 times weight through stirring for depositing, standing and filtering, washing the filter cake with acetone, stoving and grinding to obtain the breviscapine B salt. The oral preparation of the present invention is slow released high purity breviscapine B salt preparation comprising high purity breviscapine B salt 10-60 weight portions, microcrystalline cellulose 20-90 weight portions, ethyl cellulose 10-30 weight portions and acrylate resin II 2-20 weight portions.
Description
Technical field
The present invention relates to a kind of new bulk drug, and be the oral preparations that activeconstituents is made with this bulk drug.
Background technology
Chinese patent application 03112979.X discloses a kind of " lamp-dish flower acetic slow releasing tablet ", adopt lamp-dish flower acetic as activeconstituents, ether of cellulose and/or cellulose ester or polyacrylic acid crosslinked resin are made tablet as framework material with conventional auxiliary and method.Chinese patent application numbers 99122243.1 discloses " a kind of preparation method of quick soluble breviscapine B tablet "; lamp-dish flower acetic and polyethylene glycol 6000 or polyvinylpyrrolidone are prepared burden in proportion; make its dissolving with the water-bath heating; mixture is put into the refrigerator quenching; use dry method rotation nodulizer is pulverized and is granulated; use the rotary tablet machine compressing tablet, control strip weighs 0.09～0.12g, is instant.Chinese patent application numbers 200410000002.7 discloses " a kind of highly purified breviscapine B injection agent ", and described breviscapine B injection agent contains purity receivable salt on the lamp-dish flower acetic of 90.0%～99.5% (containing end points) or its physiology.
Research [Jiang Xuehua etc., Acta Pharmaceutica Sinica, 2003 that the pharmacokinetics of many pieces of report lamp-dish flower acetics is arranged in recent years, 38 (5), 371. Liu Yi is bright etc. Chinese clinical pharmacology and therapeutics .2005,10 (3), 310], it is fast that experimental result illustrates that all oral lamp-dish flower acetic absorbs, but absorption difference, about about 5%, absolute bioavailability is low greatly, metabolism is fast, transformation period is short, also has to be reported as the bioavailability that improves lamp-dish flower acetic, makes inclusion compound [Zhang Haiyan with β-ring half Hu essence, Acta Pharmaceutica Sinica, 2005,40 (6), 563], and, can improve more than 100 times of optical density by pharmacokinetic.But do not make the report of scutellarin salt and the research of formulation aspect.
Lamp-dish flower acetic is the active drug of treatment cardiovascular and cerebrovascular diseases, and the research report of relevant preparation is more, and as injection, tablet, pill, dripping pill, slow releasing tablet etc., but its Breviscarpine salt does not appear in the newspapers as yet as oral bulk drug.
Summary of the invention
Purpose of the present invention is intended to overcome the defective of prior art, and a kind of new bulk drug---high-purity scutellarin salt is provided.
Another object of the present invention is to provide the sustained release preparation made from this new bulk drug.
High-purity scutellarin salt of the present invention is the product that is made by following method: add purity in the boiling water of 3-5 times of weight greater than 99% lamp-dish flower acetic, stir evenly, add alkaline solution and transfer pH to 6.7-7.5, generate scutellarin salt, the acetone that adds the 5-10 times of weight again stirs precipitation, leave standstill, filter, filter residue is washed most mother liquor with acetone, oven dry, porphyrize, promptly.
Above-mentioned lamp-dish flower acetic purity contains given figure, and the alkaline solution that is added is weight percentage and is the alkaline solution of 10-20%, can be organic bases, as: arginine, Methionin, also can be mineral alkali, as: sodium bicarbonate, yellow soda ash or sodium hydroxide.
High-purity scutellarin salt sustained release preparation of the present invention is made up of the composition of following parts by weight: high-purity scutellarin salt 10-60 part, Microcrystalline Cellulose 20-90 part, ethyl cellulose 10-30 part, acrylic resin II numbers 2～20 parts.
In the now disclosed technical literature, involved oral Breviscapine all is to occur with the form of lamp-dish flower acetic, rather than with the form of salt.The reason of existing lamp-dish flower acetic oral preparations weak effect is because the second element is water insoluble, though absorb fast, but absorption difference, metabolism is fast, therefore influence clinical efficacy, so the present invention is directed to this problem, designing to utilize on the plain structure of second has a carboxyl can form salt, it is insoluble and cause absorption difference, fast, short this problem of transformation period of metabolism in water to solve the second element, also be to propose first high-purity scutellarin salt, and can directly use this bulk drug to make various medicinal preparationss as a kind of new bulk drug.The generation of this new bulk drug has been brought up to a new level with the preparation of lamp-dish flower acetic preparation.
Though mention the time as injection in prior art, can be with the form of scutellarin salt, but this salt and scutellarin salt of the present invention are distinguishing in essence, and the salt in the injection is to exist with ionic species, exists in solution, lose the description of its physico-chemical property, more can not become bulk drug, and scutellarin salt is solid, powdery or crystalloid, molecular formula is arranged, physical constants such as fusing point, stability might as well.
The new bulk drug that the present invention proposes with the present invention is as unique activeconstituents, and designs the enteric-coated sustained release capsule, medicine do not decomposed under one's belt, and slowly discharge in colon, keeps finite concentration in the blood, and the curative effect of preparation is got a greater increase.
Embodiment
Embodiment 1: take by weighing purity and be 99.46% lamp-dish flower acetic 500g, add in the 2500ml boiling water, adding 10% arginine aqueous solution accent pH is 6.8, adds the acetone of 10 times of weight after the dissolving, stir, precipitation left standstill 5 hours, filtered, precipitation is washed most mother liquor with acetone, 60 ℃ of dryings, porphyrize is the high-purity scutellarin arginic acid salt.
Embodiment 2: taking by weighing purity is 99.46% lamp-dish flower acetic 500g, adds in the 2000ml boiling water, adds 20% sodium hydrogen carbonate solution and transfers pH to 7, dissolving filters, and filtrate adds 8 times of amount acetone, stir, precipitation left standstill 5 hours, filtered, precipitation is washed most mother liquor with acetone, oven dry, porphyrize is the lamp-dish flower acetic sodium salt.
Embodiment 3: the high-purity scutellarin salt 60g, microcrystalline cellulose 80g, ethyl cellulose 20g, the acrylic resin II 10g that get embodiment 1.
Preparation method: high-purity scutellarin salt and Microcrystalline Cellulose are added an amount of starch paste mixing, make softwood, sieve, oven dry is then with ethyl cellulose with add adequate amount of ethanol for acrylic resin II number and dissolve, dressing, oven dry adds an amount of talcum powder, mixes thoroughly, and be sub-packed in the enteric coated capsule, be high-purity scutellarin arginic acid salt enteric-coated sustained release soft capsule.
Embodiment 4: the high-purity scutellarin salt 40g, microcrystalline cellulose 80g, ethyl cellulose 15g, the acrylic resin II 10g that get embodiment 2.
Preparation method according to embodiment 3 makes high-purity scutellarin sodium salt enteric soft capsule.
Claims (4)
1. high-purity scutellarin salt, it is characterized in that it being the product that makes by following method: purity is added in the boiling water of 3-5 times of weight greater than 99% lamp-dish flower acetic, stir evenly, add alkaline solution and transfer pH to 6.7-7.5, generate scutellarin salt, the acetone that adds the 5-10 times of weight again stirs precipitation, leaves standstill, and filters, filter residue is washed most mother liquor with acetone, oven dry, porphyrize, promptly.
2. high-purity scutellarin salt as claimed in claim 1 is characterized in that described alkali is arginine or Methionin.
3. high-purity scutellarin salt as claimed in claim 1 is characterized in that described alkali is sodium bicarbonate, yellow soda ash or sodium hydroxide.
4. high-purity scutellarin salt sustained release preparation is characterized in that being made up of the composition of following parts by weight: high-purity scutellarin salt 10-60 part, Microcrystalline Cellulose 20-90 part, ethyl cellulose 10-30 part, acrylic resin II numbers 2～20 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100661930A CN101148459A (en) | 2007-09-14 | 2007-09-14 | High-purity scutellarin salt and slow release preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100661930A CN101148459A (en) | 2007-09-14 | 2007-09-14 | High-purity scutellarin salt and slow release preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101148459A true CN101148459A (en) | 2008-03-26 |
Family
ID=39249170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100661930A Pending CN101148459A (en) | 2007-09-14 | 2007-09-14 | High-purity scutellarin salt and slow release preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101148459A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101683332B (en) * | 2008-09-26 | 2012-04-04 | 昆明龙津药业股份有限公司 | high purity scutellarin salt bulk drug and preparation method thereof |
| CN101585859B (en) * | 2008-05-22 | 2012-07-04 | 昆明制药集团股份有限公司 | Novel scutellarin derivative as well as preparation method and pharmaceutical composition thereof |
| CN101585860B (en) * | 2008-05-22 | 2013-04-10 | 昆明制药集团股份有限公司 | 4',5,6-trimethoxy scutellarin as well as preparation method and pharmaceutical composition thereof |
| CN104086611A (en) * | 2014-06-03 | 2014-10-08 | 昆明制药集团股份有限公司 | Apigenin-7-O-beta-D-glucuronide derivative, and preparation method and application thereof |
| CN105399788A (en) * | 2015-12-29 | 2016-03-16 | 云南生物谷药业股份有限公司 | Scutellarin sodium salt crystal I and preparation method thereof |
-
2007
- 2007-09-14 CN CNA2007100661930A patent/CN101148459A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101585859B (en) * | 2008-05-22 | 2012-07-04 | 昆明制药集团股份有限公司 | Novel scutellarin derivative as well as preparation method and pharmaceutical composition thereof |
| CN101585860B (en) * | 2008-05-22 | 2013-04-10 | 昆明制药集团股份有限公司 | 4',5,6-trimethoxy scutellarin as well as preparation method and pharmaceutical composition thereof |
| CN101683332B (en) * | 2008-09-26 | 2012-04-04 | 昆明龙津药业股份有限公司 | high purity scutellarin salt bulk drug and preparation method thereof |
| CN104086611A (en) * | 2014-06-03 | 2014-10-08 | 昆明制药集团股份有限公司 | Apigenin-7-O-beta-D-glucuronide derivative, and preparation method and application thereof |
| CN104086611B (en) * | 2014-06-03 | 2016-08-24 | 昆药集团股份有限公司 | Herba Erigerontis A prime derivant and preparation method thereof and purposes |
| CN105399788A (en) * | 2015-12-29 | 2016-03-16 | 云南生物谷药业股份有限公司 | Scutellarin sodium salt crystal I and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101148459A (en) | High-purity scutellarin salt and slow release preparation | |
| CN102847163B (en) | Film coating agent for hygroscopic solid traditional Chinese medicine preparation and preparation method thereof | |
| CN101502491B (en) | Dirithromycin enteric-coated formulation | |
| CN102058604A (en) | Drug composition containing dienogest and estradiol valerate and preparation method thereof | |
| CN102558154B (en) | Lansoprazole crystalline compound, enteric capsule thereof and preparation method of Lansoprazole crystalline compound | |
| CN102727457B (en) | A stable ulipristal preparation | |
| CN102343093B (en) | Seaweed polysaccharide medicinal plant film coating and preparation method thereof | |
| CN101744852A (en) | Preparation method of acanthopanax effervescent tablet and products thereof | |
| CN103705580A (en) | Moistureproof coating method of traditional Chinese medicine capsule | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN106551915A (en) | Enteric-coated composition and preparation method thereof | |
| CN101416950B (en) | Preparation method of cmellia sponin controlled release tablets | |
| CN100500195C (en) | Medicinal Smilax indica micro pill and its preparing method | |
| CN108295035A (en) | Procaterol Hydrochloride piece and preparation method thereof | |
| WO2022160397A1 (en) | Shanzhuang lipid-lowering micropellet and preparation method therefor | |
| CN102895202A (en) | Cefetamet pivoxil hydrochloride dispersible tablet and preparation method thereof | |
| CN101703475A (en) | Chondroitin sulfate pellet and preparation method thereof | |
| CN101461814B (en) | Medicament composition containing losartan and hydrochlorothiazidum | |
| CN110169954B (en) | Stable-dissolution pyrazinamide tablet and preparation method thereof | |
| CN105982904B (en) | A kind of medicament pellet composition of spirolactone | |
| CN102258493A (en) | Salidroside slow release tablets and preparation method thereof | |
| CN100512815C (en) | Matrine enteric-coated tablet and preparation method thereof | |
| CN101249119A (en) | Compound compound paracetamol and zincgluconate dispersible tablet and method of preparing the same | |
| CN101015562A (en) | DiAo Xinxuekang soft capsule and preparation process and use thereof | |
| CN105194647A (en) | Medicine composition containing isinopril and amlodipine besylate and preparation method of medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: KUNMING LONGJIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FAN XIANE Effective date: 20100512 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650228 KUNMING LONGJIN PHARMACEUTICAL CO., LTD., WUJIADUI, XINWEN ROAD (LOWER SECTION), KUNMING CITY, YUNNAN PROVINCE TO: 650106 NO.2188, KEGAO ROAD, HIGH-TECH. ZONE, KUNMING CITY, YUNNAN PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20100512 Address after: 650106 No. 2188 Gao Lu, hi tech Zone, Yunnan, Kunming Applicant after: Kunming Longjin Pharmaceutical Co., Ltd. Address before: 650228, Yunnan City, Kunming province road under the five pile of Kunming Long Jin Pharmaceutical Co., Ltd. Applicant before: Fan Xiane |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080326 |